Histidine

Histidine

SCHEMBL2804663

N[C@@H](Cc1c[nH]cn1)C(=O)O.[Mg]

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.46
SLC7A5 Q01650 3/20 0.46
CYP1A2 P05177 1/20 0.45
KDM4E B2RXH2 3/20 0.42
LMNA P02545 3/20 0.42
MAPT P10636 3/20 0.42
BLM P54132 3/20 0.42
PMP22 Q01453 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 3/20 0.42
USP2 O75604 2/20 0.42
HIF1A Q16665 2/20 0.42
MEN1 O00255 2/20 0.42
PKM P14618 2/20 0.42
ALOX15 P16050 2/20 0.42
NFKB1 P19838 2/20 0.42
ALDH1A1 P00352 2/20 0.42
NPSR1 Q6W5P4 2/20 0.42
RGS12 O14924 1/20 0.42
CYP2C9 P11712 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL388561 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL18824897 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL3258 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL388563 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL8080341 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL3259 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL163443 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL163442 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL995910 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA
Histidine SCHEMBL8316642 0.98 SLC7A5 (0.47) CYP3A4SLC7A5CYP1A2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114354533-B Meat enzymolysis pet food with antioxidant activity and preparation process thereof 弘煋科技(北京)有限公司 2023-04-28 CN claimed
CN-114354533-A Meat enzymolysis pet food with antioxidant activity and preparation process thereof 弘煋科技(北京)有限公司 2022-04-15 CN claimed
CN-117110233-B Meat enzymolysis pet food technology containing XN2 for measuring and controlling oxidation activity of release substances 上海福贝宠物用品股份有限公司 2024-12-06 CN disclosed
CN-117110233-A Meat enzymolysis pet food technology containing XN2 for measuring and controlling oxidation activity of release substances 弘煋科技(北京)有限公司 2023-11-24 CN disclosed
US-20230145406-A1 DIVALENT METAL-CONTAINING BIOMATERIALS AND METHODS OF USE UNIVERSITY OF OREGON (US) 2023-05-11 US disclosed
CN-114354533-B Meat enzymolysis pet food with antioxidant activity and preparation process thereof 弘煋科技(北京)有限公司 2023-04-28 CN disclosed
CN-114354533-A Meat enzymolysis pet food with antioxidant activity and preparation process thereof 弘煋科技(北京)有限公司 2022-04-15 CN disclosed
US-20170204127-A1 COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS SYNTHONICS INC (US) 2017-07-20 US disclosed
US-9624256-B2 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients SYNTHONICS, INC. (US) 2017-04-18 US disclosed
US-20140274936-A1 COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS SYNTHONICS, INC. (US) 2014-09-18 US disclosed
US-8779175-B2 Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients SYNTHONICS, INC. (US) 2014-07-15 US disclosed
EP-2579864-A1 COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS Synthonics, Inc. (US) 2013-04-17 EP disclosed
WO-2011149757-A1 COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS SYNTHONICS, INC. (US) 2011-12-01 WO disclosed
US-20100240601-A1 Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients SYNTHONICS, INC. 2010-09-23 US disclosed
US-20090182044-A1 NITRATE AMINO ACID CHELATES ALBION INTERNATIONAL, INC. 2009-07-16 US disclosed
WO-2009089493-A2 NITRATE AMINO ACID CHELATES ALBION INTERNATIONAL, INC. (US) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090182044-A1 NITRATE AMINO ACID CHELATES NPPA, ARG1, MAX CYP3A4 2484/4885SLC7A5 68/4885CYP1A2 1602/4885
US-20170204127-A1 COORDINATION COMPLEXES, PHARMACEUTICAL SOLUTIONS COMPRISING COORDINATION COMPLEXES, AND METHODS OF TREATING PATIENTS PDE8A, MC2R, PKD1 CYP3A4 1496/4885SLC7A5 1456/4885CYP1A2 3377/4885
US-20100240601-A1 Coordination Complexes, Pharmaceutical Solutions Comprising Coordination Complexes, and Methods of Treating Patients PDE8A, MC2R, PKD1 CYP3A4 1496/4885SLC7A5 1456/4885CYP1A2 3377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.